The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Category Archives: Transhuman News
Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled…
Posted: December 13, 2019 at 2:39 pm
NEWTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced data presented from INSPIRE related abstracts at the American Society of Hematology (ASH) 2019 Annual Meeting. Preliminary genomics data from the INSPIRE Trial was presented. In addition, updated data from the Phase 2 Trial of Oral Rigosertib + Azacitidine (AZA) Versus Single Agent AZA in Treatment-Naive Patients with HR-MDS was presented in an oral presentation. The Company believes these abstracts represent important progress for the development programs of intravenous (IV) and oral rigosertib.
Abstract #3015. Genomic Profiling in Patients with Higher Risk Myelodysplastic Syndrome Following HMA Failure: Baseline Results From the INSPIRE Trial. At study entry, 50 different mutations were identified at baseline prior to patients receiving study treatment with either IV rigosertib or physicians choice (PC). The average number of mutations per patient was 3. The most common mutations identified in patients were ASXL1 39%, TP53 27%, RUNX1 25%, STAG2 21%, SRSF2 19%, TET2 19%, DNM3A 15%, IDH2 13% and U2AF1 12%. In total 31 patients (19%) had mutations that are part of RAS pathway (NRAS, 4 pts; KRAS, 5 pts; CBL, 7 pts; PTPN11, 7 pts; NF1, 8 pts).
Genomic abnormalities have revolutionized our understanding of the biology and prognosis of patients with MDS. Abnormalities involving the RAS pathway are seen in patients with MDS who have a very poor prognosis. The INSPIRE Trial has catalogued the abnormalities seen in patients with MDS who have failed the standard of care AZA. On-going studies will determine if the research drug rigosertib can target these abnormalities and prolong the lives of patients who have the spectrum of abnormalities that have been identified, said Guillermo Garcia-Manero, M.D., Department of Leukemia, The University of Texas MD Anderson Cancer Center.
Abstract #4249. Phase II Study of Oral Rigosertib Combined with Azacitidine As First Line Therapy in Patients with HR-MDS. In HMA nave higher risk MDS patients who require the standard of care with AZA, the combination of oral rigosertib > 840 mg and AZA produced an overall response rate of 90% and a complete response (CR) rate of 34%. CR by definition signifies the patient has a normal appearing bone marrow and the marrow produces a normal peripheral blood count. The median duration of response is 12.2 months. The Company believes these data support the design of a planned Phase 2/3 adaptive trial in HR-MDS.
Efforts to improve the response rate with single agent AZA is an area of active research. The efficacy and safety data of the doublet of oral rigosertib and AZA warrants further investigation in a pivotal trial of this novel combination compared to AZA alone. If the preliminary efficacy of the doublet is confirmed in a pivotal controlled study and has an acceptable safety profile, patients with HMA nave higher risk MDS may have an important new treatment option, said Lewis Silverman, M.D., Director of Translational Research Center for MDS, Division of Hematology/Oncology, at the Icahn School of Medicine at Mount Sinai.
Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, said, ASH 2019 was a key milestone for Onconova. The five presentations at ASH showcase the value of our development programs for intravenous and oral rigosertib. The genomic data from the INSPIRE Trial identifies the most common mutations in HR-MDS following AZA failure, including those of the RAS pathway that are targeted by rigosertib. We believe the oral rigosertib in combination with AZA Phase 2 data forms the foundation of a future adaptive trial in HMA nave HR-MDS patients. We appreciate the recognition by ASH reviewers of the value of our studies in this field.
Three additional abstracts being presented at the ASH 2019 Annual Meeting include:
Abstract #4249. The Inspire Study in HR MDS: A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults.
Abstract #4268. Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Nave Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS).
Abstract #4231. The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Advanced clinical trials with the Companys lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.
For more information, please visit http://www.onconova.com.
About Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. It is frequently associated with the presence of blasts or leukemic cells in the marrow. This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anemia). Patients with higher-risk MDS may progress to the development of acute leukemia.
About Rigosertib
Rigosertib, Onconovas lead candidate, is a proprietary Phase 3 small molecule. A key publication in a preclinical model described rigosertibs ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling." Cell 165, 643). Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.
About the INSPIRE Phase 3 Clinical Trial
The clinical trial INternational Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician's Choice plus Best Supportive Care. The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion. Full details of the INSPIRE trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443).
About IV Rigosertib
The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDSafter failure of HMA therapy.
About Oral Rigosertib
The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. This dosage form may also support combination therapy modalities. To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials. Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy. A Phase 1/2 trial of the combination therapy has been fully enrolled, and the updated efficacy and safety data was presented at the ASH 2019 Annual Meeting in December 2019.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova expectations regarding the INSPIRE Trial and Onconovas other development plans. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova's ability to continue as a going concern, maintain its Nasdaq listing, the need for additional financing, the success and timing of Onconova's clinical trials and regulatory approval of protocols, our collaborations, and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
General Contact:Avi OlerOnconova Therapeutics, Inc. 267-759-3680ir@onconova.ushttp://www.onconova.com/contact/
Posted in Genome
Comments Off on Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled…
Thick, scaly patches appearing on your skin? It’s psoriasis – The Star Online
Posted: at 2:18 pm
I have never had any skin problems before in all my life. Then I was put on a beta-blocker drug and one of the side effects I got was some patches on my body and scalp. The doctor said it was psoriasis. What is that?
Psoriasis is actually a common skin condition.
It develops when the life cycle of your skin cells is speeded up, causing them to die and build up on your skin surface quickly.
These extra skin cells form scales on your skin, as well as red patches, which can be itchy, and even painful.
What is the difference between psoriasis and eczema?
Psoriasis has well-defined, thick, red and scaly patches, especially at your elbows and knees.
The patches can also appear on your face, buttocks, palms, soles and scalp.
Your skin is thicker and more inflamed than those with eczema.
Eczema also causes your skin to be red and inflamed. It is sometimes scaly, but it can also be oozing or crusty.
There may be swelling or dark, leathery patches.
Eczema tends to appear in the crooks (or inner parts) of your knees and elbows, i.e. the parts of your body that bend.
However, it can also appear on your neck, wrists, ankles and other places on babies.
Eczema is more commonly associated with children.
The itching in eczema is also more intense than in psoriasis.
Stress is one of the major factors that contribute to the triggering or worsening of psoriasis. VisualHunt.com
I heard that there are many types of psoriasis. Is this true?
Yes, everyone has different manifestations of psoriasis.
We know already that the distinct common feature is red, scaly patches on your skin due to overproduction of skin cells.
Plaque psoriasis is the commonest form. The red, silvery scaly patches are called plaques.
These plaques can occur on any part of your body, including inside your mouth and on your genitals.
There is also nail psoriasis. Obviously, this affects your fingernails and toenails, and can cause abnormal nail growth, pits (little holes) and discolouration of your nails.
Your nails can also separate from your nail bed, or even crumble entirely.
When the psoriasis patches are not formed in plaques, but in waterdrop-shaped lesions instead, it is called guttate psoriasis.
This affects young children and young adults. It is usually triggered by a bacterial infection such as a sore throat.
The skin lesions are not as thick as plaque psoriasis.
Then there is inverse psoriasis, which affects the skin on your armpits, groin, under your breasts or around your genitals.
These become worse with friction or sweating, like if you wear tight clothing.
This one has a correlation with fungal infections.
One uncommon type is pustular psoriasis. This one has pus-filled blisters on top of your red skin.
It can get quite bad because it may be associated with fever, severe itching and diarrhoea.
The rarest type is also one of the worst due to the way it looks, called erythrodermic psoriasis.
This one covers your entire body with a red rash that peels easily. It can also unfortunately itch or burn badly.
I know a relative with psoriasis who also has joint pain. Does psoriasis give rise to joint pain?
Some psoriasis patients can also suffer from joint pain due to their condition. TPNYes, this is called psoriatic arthritis. It does not happen in all psoriatic cases.
It is not as bad as rheumatoid arthritis, but can be severe as well.
This type of joint pain affects any joint. The underlying issue is inflammation and erosion of your joints.
This leads to stiffness, swelling and worsening deformity.
What is the cause of psoriasis?
No one really knows, but it is believed to be an autoimmune disease.
Your white blood cells called T lymphocytes and neutrophils attack healthy skin cells by mistake.
They travel to your skin, causing your blood vessels to dilate and your skin cells to overproduce.
That is why you have redness, swelling, and even pus it is as though your body is fighting off a skin infection.
There is also a genetic element in psoriasis. If your parents had psoriasis, you are more likely to have it too.
Is there anything that triggers psoriasis? I was told it was because of the medication I took.
Many things can trigger psoriasis, especially if you have an underlying genetic predisposition for it already.
We have already discussed that sore throats caused by bacteria, especially Streptococcus, can trigger it.
So can skin infections and injuries, like burns, sunburns, bites and cuts.
Stress can also trigger psoriasis. So can smoking and alcohol.
The types of medicines that can trigger it include beta-blockers, used for high blood pressure; lithium, used for psychotic disorders; and drugs used for malaria.
There is unfortunately no cure for psoriasis, but you can moisturise your skin, give up smoking and alcohol, stop taking those medications giving you psoriasis, and manage your stress levels, to help manage your condition.
Dr YLM graduated as a medical doctor, and has been writing for many years on various subjects such as medicine, health, computers and entertainment. For further information, email starhealth@thestar.com.my. The information contained in this column is for general educational purposes only. Neither The Star nor the author gives any warranty on accuracy, completeness, functionality, usefulness or other assurances as to such information. The Star and the author disclaim all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.
We're sorry, this article is unavailable at the moment. If you wish to read this article, kindly contact our Customer Service team at 1-300-88-7827. Thank you for your patience - we're bringing you a new and improved experience soon!
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 7
Cxense type: free
User access status: 3
Originally posted here:
Thick, scaly patches appearing on your skin? It's psoriasis - The Star Online
Posted in Psoriasis
Comments Off on Thick, scaly patches appearing on your skin? It’s psoriasis – The Star Online
Cancer And Psoriasis: Is There A Link Between The Two? – Medical Daily
Posted: at 2:18 pm
According to the National Psoriasis Foundation, more than eight million Americans suffer from psoriasis, a chronic skin condition marked by flare-ups onthe knees, elbows and scalp. Psoriasis is the byproduct of genetic factors exacerbated by stress, depression, trauma and other medical conditions.
Not focusing on the relationship between other comorbidities, a study published in October by JAMA Dermatology analyzed the link between cancer and organ-specific psoriasis, a correlation not been thoroughly established before.
As per scientists, since psoriasis is developed through inflammation, also linked to cancer risk, there could be an association between the two diseases. Smoking, drinking and obesity are known risk factors for people with psoriasis, apart from immunomodulatory and potentially carcinogenic treatments.
In fact, a systematic review done in the past was limited to only people with psoriatic arthritis, and omitted autoimmune conditions. The recent comprehensive meta-analysis by University of Manchester aimed to ascertain susceptibility to cancer among people who suffering from psoriasis.
What The Study Found
The review included 58 observational studies, of which 50 had participants with cancer, 15 reported cancer mortality and 7 studieshad both. These studies were adjusted and grouped together based on several overlapping factors. Studies were grouped into level 1 based on adjustments for age and sex. Level 2 studies were adjusted based on age, sex and risk factors such as smoking, alcohol and obesity.
The overall risk of developing cancer was significantly elevated in people with psoriasis and for a number of site-specific cancers; the risk of cancer mortality was found to be elevated in those with severe psoriasis, the researchers stated in the paper.
With regard to site-specific cancers, we observed elevated incident cancer risks for lymphoma, keratinocyte, esophageal, liver, and pancreatic cancers in studies of severe psoriasis and in those involving people with all severities of psoriasis. Similarly, esophageal, liver, and pancreatic cancers also demonstrated an increased risk when considering cancer mortality in studies of severe psoriasis, the researchers added further in the paper.
Evidence from cohort studies of severe psoriasis indicated a 1.22-fold increased risk of developing cancer when compared with populations without psoriasis, a result not significantly different from that of all psoriasis severities. With regard to cancer mortality, a 1.22-fold increased risk of dying due to cancer compared with psoriasis-free populations was observed in studies of severe psoriasis, the researchers explained.
The evidence from this meta-analysis not only suggests that cancer should be given more consideration as an important comorbidity of psoriasis but also begins to present evidence that this risk could be alleviated to some extent through lifestyle behavior change, they concluded.
Plaque psoriasis can be itchy and painful. Image courtesy of Pixabay, public domain
Go here to see the original:
Cancer And Psoriasis: Is There A Link Between The Two? - Medical Daily
Posted in Psoriasis
Comments Off on Cancer And Psoriasis: Is There A Link Between The Two? – Medical Daily
Serious Infection Risk in Psoriasis and PsA Patients Using Biologics – DocWire News
Posted: at 2:18 pm
A recent retrospective cohort analysis explored the association between risk of serious infection and initiation of interleukin (IL)-17, IL-12/23, and tumor necrosis factor (TNF) inhibitor among real-world patients with psoriasis or psoriatic arthritis (PsA).
Commercially insured patients diagnosed with psoriasis or PsA between 2015 and 2018 were included in the study. The exposure was defined as dispensation for IL-17 (ixekizumab or secukinumab), IL-12/23 (ustekinumab) or TNF (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab). The primary outcome was infection requiring hospitalization after biologic initiation. The researchers calculated incidence rates (IRs) per 100 person-years. Cox proportional hazards regression models were adjusted for inverse probability of treatment-weighted propensity scores.
Final analysis included 11,560 new treatment episodes; during 9,264 person-years of follow-up, 190 serious infections (2% of treatment episodes) were reported. Between IL-17 and TNF, class-specific IRs did not significantly differ, but were significantly lower for IL-12/23. In adjusted analyses, infection risk with IL-17 was not significantly greater compared to TNF (hazard ratio [HR]=0.89; 95% CI, 0.48 to 1.66) or IL-12/23 (HR=1.12; 95% CI, 0.62 to 2.03). Compared to TNF, IL-12/23 was associated with a reduced risk of infection (HR=0.59; 95% CI, 0.39 to 0.90).
Relative to TNF and IL-17, IL-12/23 inhibitors were associated with a reduced risk of serious infection in biologic-nave patients with [psoriasis] or PsA, the researchers concluded. In biologic-experienced individuals, there was no difference in infection risk across TNF, IL-17 or IL-12/23 inhibitors.
The rest is here:
Serious Infection Risk in Psoriasis and PsA Patients Using Biologics - DocWire News
Posted in Psoriasis
Comments Off on Serious Infection Risk in Psoriasis and PsA Patients Using Biologics – DocWire News
Immunogenicity and Safety of Vaccination against Seasonal Influenza Vaccine in Patients with Psoriatic Arthritis Treated with Secukinumab – DocWire…
Posted: at 2:18 pm
OBJECTIVE:
To assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab versus healthy controls (HC).
PsA patients administered secukinumab for 3months and HC received the Sanofi Pasteur vaccine composed of 3 antigens (H3N3, H1N1, and B) and underwent clinical and laboratory assessments on the day of vaccination and 4-6weeks later. Immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay against those 3 antigens. Responders to each antigen were defined by a 4-fold increase in the antigen titer or by seroconversion in patients whose baseline level was <1/40.
Thirty-two consecutive PsA patients treated with secukinumab for 3months comprised the study group, 10 of whom received concomitant conventional synthetic disease-modifying drugs, mostly methotrexate. There were 17 age- and gender-matched HC (median age 48.5years, 6 females). The geometric mean titers of each antigen increased significantly in both groups. The number of responders in each group was similar for H3N2 and H1N1, and significantly higher for B/Brisbane in the PsA group. The proportion of patients with a seroprotective level (a titer >1/40) was high and similar in both groups. There was no correlation between the response rate and age, gender, or selected parameters of disease activity (tender/swollen joint counts, Leeds enthesitis index, physician and patient global assessment, psoriasis area severity index, and C-reactive protein). No disease exacerbation was observed following the vaccination. No serious adverse effects were observed in both groups during the study period.
Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA.
See the original post:
Immunogenicity and Safety of Vaccination against Seasonal Influenza Vaccine in Patients with Psoriatic Arthritis Treated with Secukinumab - DocWire...
Posted in Psoriasis
Comments Off on Immunogenicity and Safety of Vaccination against Seasonal Influenza Vaccine in Patients with Psoriatic Arthritis Treated with Secukinumab – DocWire…
Here is how turning vegan cured Paula’s psoriasis – Lancashire Post
Posted: at 2:18 pm
After years of feeling self conscious and sore due to her psoriasis, Paula Taylor was willing to try anything to find a cure. And after two weeks of sticking to a vegan diet, she was amazed by the results, as her skin completely cleared.
Paula Taylor, of Ashton, was only 11 when she started to get a severe rash on her skin.
Possibly brought on by grief after losing her nana, doctors thought she had the shingles until she was hospitalised for further treatment.
As she had to undergo a strict and lengthy treatment regime at home, Paula admits to losing part of her childhood.
The 49-year-old, who works at The Hidden Jem, in Lytham, had suffered with the skin condition since she was 11 and had even been hospitalised as she had cold tar treatment.
She recalls: Nobody knew what it was at first, as psoriasis was not widely known.
I lost my nan and it was linked to grief. I had just started high school and I was very conscious about it.
I didnt want to do sport as I didnt want anyone to see me in the shower. It was extremely uncomfortable and itchy, as it was in my hair, under my breasts and down my back.
It came down my hairline and had gone up my neck, so I could not cover it up. My school uniform is black, so I had severe dandruff and I was bullied.
At one time, I was hospitalised for 12 weeks and had to have coal tar baths.
I didnt have much of an adolescence as I was not able to socialise much. I felt very isolated. I did have a few good friends, who I still see now. They would sit around while I was in the house having my treatment put on.
I managed to get better with the treatments until I was 18/19. But as other women were going out and spent ages getting ready, wearing fake tan and perfume, I was putting on cold tar and had greasy hair which smelt. It was not fun.
In her late teens, Paula began to work at The Waterfront pub on Preston docklands, where she met her first boyfriend.
But when they broke up, her psoriasis flared up.
She reveals: I was mortified and the psoriasis came back. I was hospitalised for longer but it got better with treatment.
I had to put the coal tar on and lie there for six hours until I could take it off.
Paula and her boyfriend got back together and they moved to Herefordshire, working in different pubs when she was 21.
She sailed through life again, as they got married and had two children and she set up her own clothes boutique.
Whilst the psoriasis was always there, she was able to keep it under control.
But four years ago, Paula faced a more stressful time, as she split from her husband and moved back to Preston.
She says: I went through a traumatic time as I was going through a divorce. We are still friends but we grew apart and he worked away a lot.
I had all that trauma going on and I was struggling again with psoriasis. I was always sore internally and my body was inflamed. It was getting better in the summer when the sun was getting to my skin and I was eating healthier and doing a lot of exercise. But my skin would be bad in winter.
I would be drinking more as I was uncomfortable and eating unhealthily.
Paula started to get her life back on track and although she struggled at first to find a job, she started working at The Hidden Jem, in Lytham.
But in February, she developed strep throat and she was suffering from anxiety, which caused the psoriasis to return.
She adds: I had to take one day a week off to have an appointment with my GP and start with the steroid cream. It was so soul destroying and painful.
It was beginning to have an impact on my self worth. I never felt clean as I had treatment on. The only place I felt comfortable was in the bath.
So I began researching.
Thats when I found Hanna Sillitoe, who had started her own blog, and it was like reading my own story, as she struggled with psoriasis. I read My Goodness Recipes and Radiant, as she went through the process of elimination in her diet.
She started juicing and cleansing, so I bought a juicer on eBay.
I went cold turkey and juiced every day. I was drinking celery juice, cucumber, apple juice, and spinach juice. I had that three times for three days and I was drinking so much water in between to cleanse. Then I had soups and salads every day for a fortnight.
I had no dairy, meat or alcohol and within 17 days, my psoriasis was clear. It felt like a miracle.
I felt incredible and nothing hurt anymore.
Paula has now been following a vegan-based diet and combined with simple coconut and salt baths, her psoriasis has been kept at bay.
She also lost a significant amount of weight, dropping from a size 20 to a size 10.
She admits: I follow the rules but I fall off the wagon every now and again as you have to have a good life balance. You dont have to be so stringent, so I may have a drink, but I know what to do if I get too bad, as I just go on a juice diet for a few days.
You can stop eating something for a few days, then reintroduce and stop something else.
The feeling I have now is worth giving up a few ingredients, as it is beneficial to my health.
Hanna Sillitoe had suffered from severe psoriasis, eczema and acne for more than 20 years.
When her doctor told her the only remaining treatment was chemotherapy, she began researching diet and skin, which produced dramatic results.
Now free from all skin complaints, she compiled a book, Radiant, which features a detailed 28 day life changing plan alongside more than 100 skin focused recipes.
She has also appeared on Dragons Den, pitching her concept, which also includes natural, botanical skin care products.
For more information visit http://www.hannasillitoe.com.
Read more:
Here is how turning vegan cured Paula's psoriasis - Lancashire Post
Posted in Psoriasis
Comments Off on Here is how turning vegan cured Paula’s psoriasis – Lancashire Post
Elon Musk Is Talking About Powering All of America with Solar – Futurism
Posted: at 2:00 pm
Solar U.S.A.
Elon Musk is talking, again, about his idea to turn 10,000 square miles in the U.S. desert into a solar farm that can power the entire nation. In a Saturday Twitter reply to an article by Treehugger about Bill Gates questioning the efficiency of solar power, Musk fired back that all you need is a 100 by 100 mile patch in a deserted corner of Arizona, Texas or Utah (or anywhere) to more than power the entire USA.
He first talked about the idea in 2015, and reiterated them in 2017, as Inverse points out. The batteries you need to store the energy, so you have 24/7 power, is 1 mile by 1 mile, Musk said at the National Governors Association Summer Meeting in Rhode Island in 2017. One square-mile. Thats it.
Musk also linked to a University College London blog post, in which energy researcher Andrew Smith did some back-0f-the-envelope calculations, finding that a 10,000 square kilometer area far smaller than the 100 by 100 mile patch to be clear could generate about 500 Gigawatts at 21 percent efficiency, the average in Northwest Texas. Thats more than the U.S. annual average consumption of 425 GW.
But it would be an extremely expensive mega project as well. If you were to cover the patch with Teslas solar panel-covered Roof tiles, it would still cost about six trillion dollars, according to Popular Mechanics which is about the GDP of Japan.
READ MORE: Elon Musks Plan for One Giant Solar Farm Is a Little Insane, but Not Completely Insane [Popular Mechanics]
More on the idea: Elon Musk Tells National Governors Association How We Could Power the U.S. With Solar
See the original post here:
Elon Musk Is Talking About Powering All of America with Solar - Futurism
Posted in Futurist
Comments Off on Elon Musk Is Talking About Powering All of America with Solar – Futurism
SpaceX Is Delivering Cannabis to the Space Station – Futurism
Posted: at 2:00 pm
That Sticky-Icky in Space
On Sunday, a SpaceX Dragon capsule docked with the International Space Station hauling nearly three tons of cargo. SpaceXs next ISS resupply mission is scheduled for March 2020, and while that trip might not include any super-buff mighty mice, itll be packing something equally unique: cannabis.
On Tuesday, agri-tech company Front Range Biosciences announced plans to send cannabis to the ISS. No, its not space-shipping weed to get astronauts high. Instead, itll send plant cultures of hemp, the legal cannabis strain with low levels of compound THC.
The cultures will remain in an ISS incubator for 30 days while BioServe Space Technologies (a Front Range project partner) monitors them remotely from the University of Colorado, Boulder.
After their 30 days in space, the cannabis cultures go home to Earth so Front Range can see what effect, if any, microgravity and space radiation had on their gene expression.
There is science to support the theory that plants in space experience mutations, Front Range CEO Jonathan Vaught said in a release. This is an opportunity to see whether those mutations hold up once brought back to earth and if there are new commercial applications.
READ MORE: A Company Is Sending Cannabis and Coffee to Space to See if They Mutate [Motherboard]
More on cannabis: Seven Ways Cannabis Legalization Will Make the Future Better
Read the original:
SpaceX Is Delivering Cannabis to the Space Station - Futurism
Posted in Futurist
Comments Off on SpaceX Is Delivering Cannabis to the Space Station – Futurism
Middle Eastern Nation First to Buy Drone Armed With Machine Gun – Futurism
Posted: at 2:00 pm
Before the end of the year, Turkey will become the first nation to get its hands on a brand new military drone equipped with a machine gun.
Its called the Songar, and it can carry 200 rounds of ammunition. A New Scientist story notes that the drone is accurate enough to hit a human target with every bullet fired from 200 meters (656 feet) away a devastating level of accuracy in the already troubling space of drone warfare.
Songar is the work of Turkish electronics firm Asisguard, and according to the companys website, a human can control the drone from a distance of 10 kilometers (6.2 miles). Using a single controller, they can operate up to three Songars simultaneously during the day or at night, looking through the devices cameras and deciding when to fire their guns.
Asisguard equipped the drone with two systems designed to address the issue of recoil affecting accuracy. One uses a group of sensors that accountfor variablesranging from a targets distance to the current wind speed. The other uses robotic arms to manually move the gun as needed to counteract the recoil.
Songar isnt the first machine gun-equipped drone weve seen, and its easy to see why the devices appeal to militaries: with an armed drone, a soldier can attack the enemy while staying out of harms way.
But as more and more armed drones emerge, it seems like just a matter of time before militaries decide to remove human operators from the equation altogether. In fact, that may already be happening as United States Defense Secretary Mark Esper accused China in November of selling autonomous killer drones to nations in the Middle East.
So, while the drones that Asisguard plans to sell to Turkey later this month might require a human operator, theres a chance the next armed drones the nation adds to its arsenal will be autonomous and thatll be when things get really scary.
READ MORE: Turkey is getting military drones armed with machine guns [New Scientist]
More on drones: New Warfare Drones are Small as a Quadcopter
More here:
Middle Eastern Nation First to Buy Drone Armed With Machine Gun - Futurism
Posted in Futurist
Comments Off on Middle Eastern Nation First to Buy Drone Armed With Machine Gun – Futurism
Virgil Abloh Merges Fashion and Futurism with the Louis Vuitton Men’s 2054 Collection – Ocean Drive Magazine
Posted: at 2:00 pm
Imagined by Artisitc Director Virgil Abloh, Louis Vuitton Men's 2054 is a luxury lifestyle ready-to-wear collection built for the great unknown.
Fashion has long flirted with futurism. What began as a cutting-edge movement among early-20th century painters and sculptors quickly swept over the design studios and runways of Milan and Paris. It played out as a celebration of everything new, urban and industrialfabrics, designs, colors and cuts that reflected movement and speed.
But what exactly is futurism now that we are living in the future? It is here, in Louis Vuitton Mens 2054 capsule collection: 14 pieces made of 100% water-repellent technical fabrications with transformable features and multifunctional values. In the collection, Artistic Director Virgil Abloh revisits the idea of compressomorphosisfirst introduced in his pre-fall 2019 collection. The term applies to garments accessorized with wrapper bags into which they can be entirely compressed for travel purposes. For instance, the back pocket of an oversized coat unrolls into a life-size tent raised with included tent poles, the coats back-zip adornment transforming into the tent door; a padded over-shirt with multiple zips for adaptation compresses into its own back pocket and morphs into a pillow native to trekking.
The name is a nod to 1854, the year the house was founded, and signals a fusion of the past, present and future. In other words, its clienteles uniform 200 years from its point of origin. The future is now.
Pieces in the Louis Vuitton Mens 2054 collection range from $6,535 for the 3-in-1 parka to $920 for the 3D effect T-shirt, all at Louis Vuitton Design District.
Photography by: Courtesy of Louis Vuitton
Visit link:
Virgil Abloh Merges Fashion and Futurism with the Louis Vuitton Men's 2054 Collection - Ocean Drive Magazine
Posted in Futurist
Comments Off on Virgil Abloh Merges Fashion and Futurism with the Louis Vuitton Men’s 2054 Collection – Ocean Drive Magazine